Docosahexaenoic acid (DHA): An essential nutrient and a nutraceutical for brain health and diseases.
Docosahexaenoic acid (DHA), a polyunsaturated fatty acid (PUFA) enriched in phospholipids in the brain and retina, is known to play multi-functional roles in brain health and diseases. While arachidonic acid (AA) is released from membrane phospholipids by cytosolic phospholipase A2(cPLA2), DHA is linked to action of the Ca2+-independent iPLA2. DHA undergoes enzymatic conversion by 15-lipoxygenase (Alox 15) to form oxylipins including resolvins and neuroprotectins, which are powerful lipid mediators. DHA can also undergo non-enzymatic conversion by reacting with oxygen free radicals (ROS), which cause the production of 4-hydoxyhexenal (4-HHE), an aldehyde derivative which can form adducts with DNA, proteins and lipids. In studies with both animal models and humans, there is evidence that inadequate intake of maternal n-3 PUFA may lead to aberrant development and function of the central nervous system (CNS). What is less certain is whether consumption of n-3 PUFA is important in maintaining brain health throughout one's life span. Evidence mostly from non-human studies suggests that DHA intake above normal nutritional requirements might modify the risk/course of a number of diseases of the brain. This concept has fueled much of the present interest in DHA research, in particular, in attempts to delineate mechanisms whereby DHA may serve as a nutraceutical and confer neuroprotective effects. Current studies have revealed ability for the oxylipins to regulation of cell redox homeostasis through the Nuclear factor (erythroid-derived 2)-like 2/Antioxidant response element (Nrf2/ARE) anti-oxidant pathway, and impact signaling pathways associated with neurotransmitters, and modulation of neuronal functions involving brain-derived neurotropic factor (BDNF). This review is aimed at describing recent studies elaborating these mechanisms with special regard to aging and Alzheimer's disease, autism spectrum disorder, schizophrenia, traumatic brain injury, and stroke.
Biochemistry Department, University of Missouri, Columbia, MO, United States.
Grace Y
GY
Sun
Biochemistry Department, University of Missouri, Columbia, MO, United States.
Agnes
A
Simonyi
Department of Nutrition and Exercise Physiology, University of Missouri, Columbia, MO, United States.
Kevin L
KL
Fritsche
Department of Neurology, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, OH, United States.
Dennis Y
DY
Chuang
Biochemistry Department, University of Missouri, Columbia, MO, United States.
Mark
M
Hannink
Department of Pathology and Anatomical Sciences, University of Missouri School of Medicine, Columbia, MO, United States.
Zezong
Z
Gu
Chemistry Department, University of Missouri, Columbia, MO, United States.
C Michael
CM
Greenlief
Medical Research Service, VA Pittsburgh Healthcare System, and Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.
Jeffrey K
JK
Yao
Department of Bioengineering, University of Illinois at Chicago, Chicago, IL, United States.
James C
JC
Lee
Department of Radiology, Neurology, and Psychological Sciences, and the Thompson Center, William and Nancy Thompson Endowed Chair in Radiology, University of Missouri School of Medicine, Columbia, MO, United States.
David Q
DQ
Beversdorf
D000375:Aging / Q000378:metabolism*; D000818:Animals; D001921:Brain / Q000378:metabolism*; D019587:Dietary Supplements; D004281:Docosahexaenoic Acids / Q000378:metabolism* / Q000627:therapeutic use; D054522:Group VI Phospholipases A2 / Q000378:metabolism; D006801:Humans; D001523:Mental Disorders / Q000178:diet therapy / Q000378:metabolism; D018696:Neuroprotective Agents / Q000378:metabolism
D018696:Neuroprotective Agents; D004281:Docosahexaenoic Acids; D054522:Group VI Phospholipases A2; C516475:PLA2G6 protein, human
4-hydoxyhexenal (4-HHE); Alox 15; Antioxidant response element (ARE); Brain development; Brain-derived neurotropic factor (BDNF); Docosahexaenoic acid (DHA); Heme oxygenase-1 (HO-1); IPLA(2); Life spectrum; Neuroinflammation; Neuroprotectin 1 (NPD1); Nuclear factor (erythroid-derived 2)-like 2 (Nrf2); Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB); Oxidative metabolites; Oxylipins; Polyunsaturated fatty acids (PUFA); Resolving; Signaling pathways